Entropix has recently received a six-figure investment from LYVA Labs’ Health and Life Sciences Fund to support the commercialisation of its enzyme technology and to scale development activity. LYVA Labs delivers economic growth in the Liverpool City Region through the commercialisation of innovation and by supporting the ideas, people and projects that are transforming the region and shaping the future.
Speaking of the investment, Rob Rule, CEO Entropix Ltd, said: “We are delighted to receive this investment from LYVA Labs, which is testament to the progress we have made since our earlier investment from Deepbridge Capital. We have been developing our technology platform and a range of high-performance enzymes during this time. The company is ready to commercialise its own enzymes in the life science sector and has several opportunities in the pipeline to develop enzymes for a range of customers.”
Akshay Bhatnagar, Head of Investment, LYVA Labs, added: “ The opportunity to back Rob and David to develop novel enzymes for applications like plastics degradation and to optimise enzymes for their clients is a truly exciting one. Our fund was designed to support early-stage, research-focused businesses like Entropix, providing much-needed investment alongside Innovate UK grants. We look forward to working with the team as they continue to grow this exciting business.”
